Drug profile · INN
viltolarsen
VILTEPSO
viltolarsen (VILTEPSO) is a dystrophin pre-mrna positive modulator. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — viltolarsen
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
viltolarsen (VILTEPSO) is a dystrophin pre-mrna positive modulator. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Dystrophin pre-mRNA positive modulator
Primary target: Dystrophin pre-mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is viltolarsen?
viltolarsen (VILTEPSO) is a dystrophin pre-mrna positive modulator. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for viltolarsen?
VILTEPSO is a marketed brand name for viltolarsen. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of viltolarsen?
viltolarsen has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.